News und Analysen

Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market

Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market

Americans might not be as coronavirus-weary as some fear. Actually, these days they might be more coronavirus-wary. On the back of early take-up data for the latest COVID-19 vaccines that came out

Americans might not be as coronavirus-weary as some fear. Actually, these days they might be more coronavirus-wary. On the back of early take-up data for the latest COVID-19 vaccines that came out

If you had invested in a stock 10 years ago, you would expect to be sitting on some decent gains by now. The S&P 500 averages a long-term return of 10% per year. That means that over a decade of

Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer

Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer

Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).

Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).

The field of Alzheimer's disease (AD) has been where experimental drugs come to die in the past couple of decades. Many companies have tried and largely failed to develop new and effective therapies

The field of Alzheimer's disease (AD) has been where experimental drugs come to die in the past couple of decades. Many companies have tried and largely failed to develop new and effective therapies

The field of Alzheimer's disease (AD) has been where experimental drugs come to die in the past couple of decades. Many companies have tried and largely failed to develop new and effective therapies

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning.

What's

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning.

What's

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) are seeing explosive gains in Tuesday's trading following an announcement that the company is on track to be acquired by Alfasigma, a private

Shares of medical device manufacturer AngioDynamics (NASDAQ: ANGO) jumped 5.3% through 12:05 p.m. ET on Monday ahead of its expected earnings release next month. This morning, investment bank H.C

UnitedHealth Group (NYSE: UNH) has seen its shares decline more than 6% so far this year. That may not seem like much of a drop, but for a company as steady as UnitedHealth, that represents a

UnitedHealth Group (NYSE: UNH) has seen its shares decline more than 6% so far this year. That may not seem like much of a drop, but for a company as steady as UnitedHealth, that represents a